BioAtla, Inc. Share Price
BCABBioAtla, Inc. Stock Performance
Open $4.25 | Prev. Close $4.61 | Circuit Range N/A |
Day Range $4.25 - $4.45 | Year Range $0.12 - $6.07 | Volume 5,366 |
Average Traded $4.34 |
BioAtla, Inc. Share Price Chart
About BioAtla, Inc.
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
BioAtla, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
07-Apr-26 | $5.18 | $4.61 | -16.26% |
06-Apr-26 | $6.07 | $5.50 | +4,134.62% |
02-Apr-26 | $0.13 | $0.13 | +0.78% |
01-Apr-26 | $0.12 | $0.13 | -20.86% |
31-Mar-26 | $0.15 | $0.16 | +3.82% |
30-Mar-26 | $0.15 | $0.16 | +0.64% |
27-Mar-26 | $0.17 | $0.16 | -0.64% |
FAQs on BioAtla, Inc. Share Price
Can I buy BioAtla, Inc. shares in India?
What is the share price of BioAtla, Inc.?
What is the 5 year returns of BioAtla, Inc.?
What are the high & low stock price of BioAtla, Inc. today?
What is the 52-week high and low of BioAtla, Inc. stock?